The spread of coronavirus vaccines in lower-income countries may soon receive a huge boost. On Thursday, two people familiar with the matter spoke Reuters that Pfizer (NYSE: PFE) and BioNTech 09.30 NASDAQ: BNTX have agreed to provide a program led by the World Health Organization (WHO) with their COVID-19 vaccine.
The COVAX program is a group effort coordinated by the WHO, the Innovation Preparedness Innovation Coalition (CEPI) and Gavi, the Vaccine Alliance. The program aims to provide 2 billion doses by the end of this year to protect vulnerable people and frontline health workers in the participating countries. All countries are eligible to participate, but the program plans to deliver about 1
The details of the number of doses that Pfizer and BioNTech have agreed on and the price of a dose that COVAX intends to pay to partners are not yet clear. None of the companies has announced a formal agreement to supply COVAX, but it is expected to fill the gaps on Friday.
This is not the first vaccine allowed in some countries to be provided by the COVAX program. In December, the COVAX program entered into a preliminary purchase agreement with AstraZeneca (NASDAQ: AZN) for 170 million doses of a candidate coronavirus that is approved for use in the UK and India. Johnson and Johnson (NYSE: JNJ) there is also an agreement with the program to deliver 500 million doses from its applicant for a single dose of vaccine, which is expected to provide data from clinical trials at a later stage each day.